WHO PRODUCT INFORMATION

NAME OF THE MEDICINAL PRODUCT

Nimenrix™ powder and solvent for solution for injection
Meningococcal polysaccharide serogroups A, C, W-135, and Y conjugate vaccine

QUALITATIVE AND QUANTITATIVE COMPOSITION

After reconstitution, one dose (0.5 ml) contains:

Neisseria meningitidis serogroup A polysaccharide[1]	5 micrograms
Neisseria meningitidis serogroup C polysaccharide[1]	5 micrograms
Neisseria meningitidis serogroup W-135 polysaccharide[1]	5 micrograms
Neisseria meningitidis serogroup Y polysaccharide[1]	5 micrograms
[1]conjugated to tetanus toxoid carrier protein	44 micrograms

Excipients:
Powder: sucrose, trometamol
Solvent: sodium chloride, water for injections

The powder is a white powder or cake.

The solvent is a clear and colourless solution.

CLINICAL PARTICULARS

Therapeutic indications

Active immunisation of individuals from 6 weeks of age against invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A, C, W-135, and Y (see section *Pharmacodynamic properties*).

Posology and method of administration

Posology

Nimenrix™ should be used in accordance with available official recommendations.

Age Group	Primary Immunisation	Booster
Infants from 6 weeks to less than 6 months of age*	Two doses, each of 0.5 ml, with the first dose given from 6 weeks of age, with an interval of 2 months between doses	At 12 months of age
Unvaccinated infants from 6 months to less than 12 months of age**	One dose of 0.5 ml given from 6 months of age	At 12 months of age with a minimum interval of at least 2 months after the primary dose
Children from 12 months of age, adolescents and adults**	One dose of 0.5 ml	Not routinely administered

* See section "*Pharmacodynamic properties*" for further information.

In some situations, consideration may be given to administering an additional primary dose or a booster dose of ***Nimenrix™* (see sections *Special warnings and precautions for use* and *Pharmacodynamic properties* for further information).

Long-term antibody persistence data following vaccination with ***Nimenrix™*** are available up to 10 years after vaccination (see sections *Special warnings and precautions for use* and *Pharmacodynamic properties*).

Nimenrix™ may be given as a booster dose to individuals who have previously received primary vaccination with ***Nimenrix™*** or other conjugated or plain polysaccharide meningococcal vaccines (see sections *Special warnings and precautions for use* and *Pharmacodynamic properties*).

Method of administration

Nimenrix™ is for intramuscular injection only.

In infants, the recommended injection site is the anterolateral aspect of the thigh. In individuals from 1 year of age, the recommended injection site is the anterolateral aspect of the thigh or the deltoid muscle (see sections *Special warnings and precautions for use* and *Interaction with other medicinal products and other forms of interaction*).

For instructions on reconstitution of the medicinal product before administration, see section *Special precautions for disposal and other handling*.

Contraindications

Nimenrix™ should not be administered to subjects with hypersensitivity to the active substances or to any of the excipients contained in the vaccine.

Special warnings and precautions for use

Nimenrix™ should under no circumstances be administered intravascularly, intradermally or subcutaneously.

It is good clinical practice to precede vaccination by a review of the medical history (especially with regard to previous vaccination and possible occurrence of undesirable effects) and a clinical examination.

As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of a rare anaphylactic event following the administration of the vaccine.

Intercurrent illness

As with other vaccines, vaccination with ***Nimenrix™*** should be postponed in subjects suffering from an acute severe febrile illness. The presence of a minor infection, such as a cold, should not result in the deferral of vaccination.

Syncope

Syncope (fainting) can occur following, or even before, any vaccination as a psychogenic response to the needle injection. It is important that procedures are in place to avoid injury from faints.

Thrombocytopenia and coagulation disorders

As with other vaccines administered intramuscularly, ***Nimenrix™*** should be given with caution to individuals with thrombocytopenia or any coagulation disorder since bleeding may occur following an intramuscular administration to these subjects.

Immunodeficiency

It may be expected that in patients receiving immunosuppressive treatment or patients with immunodeficiency, an adequate immune response may not be elicited.

Persons with familial complement deficiencies (for example, C5 or C3 deficiencies) and persons receiving treatments that inhibit terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by *Neisseria meningitidis* groups A, C, W-135, and Y, even if they develop antibodies following vaccination with ***Nimenrix™***.

Protection against meningococcal disease

Nimenrix™ will only confer protection against *Neisseria meningitidis* serogroups A, C, W-135, and Y. The vaccine will not protect against other *Neisseria meningitidis* serogroups.

As with any vaccine, a protective immune response may not be elicited in all vaccinees.

Effect of prior vaccination with plain polysaccharide meningococcal vaccine
Subjects previously vaccinated with a plain polysaccharide meningococcal vaccine and vaccinated with ***Nimenrix™*** 30 to 42 months later had lower Geometric Mean Titres (GMTs) measured with a serum bactericidal assay using rabbit complement (rSBA) than subjects who had not been vaccinated with any meningococcal vaccine in the preceding 10 years (see section *Pharmacological properties*). The clinical relevance of this observation is unknown.

Immune response in infants aged 6 months to less than 12 months
A single dose administered at 6 months was associated with lower human complement serum bactericidal assay (hSBA) titres to groups W-135 and Y compared with three doses administered at 2, 4, and 6 months (see section *Pharmacodynamic properties*). The clinical relevance of this observation is unknown. If an infant aged 6 months to less than 12 months is expected to be at particular risk of invasive meningococcal disease due to exposure to groups W-135 and/or Y, consideration may be given to administering a second primary dose of ***Nimenrix™*** after an interval of 2 months.

Immune responses in toddlers aged 12-14 months
Toddlers aged 12-14 months had similar rabbit complement serum bactericidal assay (rSBA) titres to groups A, C, W-135, and Y at one month after one dose of ***Nimenrix™*** or at one month after two doses of ***Nimenrix™*** given two months apart.

A single dose was associated with lower hSBA titres to groups W-135 and Y compared with two doses given two months apart. Similar responses to groups A and C were observed after one or two doses (see section *Pharmacodynamic properties*). The clinical relevance of this observation is unknown. If a toddler is expected to be at particular risk of invasive meningococcal disease due to exposure to groups W-135 and/or Y, consideration may be given to administering a second dose of ***Nimenrix™*** after an interval of 2 months. Regarding waning of antibody against group A or group C after a first dose of ***Nimenrix™*** in children aged 12-23 months, see under Persistence of serum bactericidal antibody titres.

Persistence of serum bactericidal antibody titres

Following administration of ***Nimenrix™*** there is a waning of serum bactericidal antibody titres against group A when using hSBA (see section *Pharmacodynamic properties*). The clinical relevance of this observation is unknown. However, if an individual is expected to be at particular risk of exposure to group A and received a dose of ***Nimenrix™*** more than approximately one year previously, consideration may be given to administering a booster dose.

A decline in antibody titres over time has been observed for groups A, C, W-135, and Y. The clinical relevance of this observation is unknown. A booster dose might be considered in individuals vaccinated at toddler age remaining at high risk of exposure to meningococcal disease caused by groups A, C, W-135 or Y (see section *Pharmacodynamic properties*).

Effect of ***Nimenrix™*** on anti-tetanus antibody concentrations

Although ***Nimenrix™*** contains tetanus toxoid, this vaccine does not substitute for tetanus immunisation.

Giving ***Nimenrix™*** with or one month before a TT-containing vaccine in the second year of life does not impair the response to TT or significantly affect safety. No data are available beyond the age of 2 years.

Sodium content

This vaccine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodium-free’.

Interaction with other medicinal products and other forms of interaction
In infants, ***Nimenrix™*** can be given concomitantly with combined DTaP-HBV-IPV/Hib vaccines and with 10-valent pneumococcal conjugate vaccine.

From age 1 year and above, ***Nimenrix™*** can be given concomitantly with any of the following vaccines: hepatitis A (HAV) and hepatitis B (HBV) vaccines, measles - mumps - rubella (MMR) vaccine, measles - mumps - rubella - varicella (MMRV) vaccine, 10-valent pneumococcal conjugate vaccine or unadjuvanted seasonal influenza vaccine.

In the second year of life, ***Nimenrix™*** can also be given concomitantly with combined diphtheria - tetanus - acellular pertussis (DTaP) vaccines, including combination DTaP vaccines with hepatitis B, inactivated poliovirus or *Haemophilus influenzae* type b (HBV, IPV or Hib), such as DTaP-HBV-IPV/Hib vaccine and 13-valent pneumococcal conjugate vaccine.

In individuals aged 9 to 25 years, ***Nimenrix™*** can be given concomitantly with human papillomavirus bivalent [Type 16 and 18] vaccine, recombinant (HPV2).

Whenever possible, ***Nimenrix™*** and a tetanus toxoid (TT) containing vaccine, such as DTaP-HBV-IPV/Hib vaccine, should be co-administered or ***Nimenrix™*** should be administered at least one month before the TT-containing vaccine.

One month after co-administration with a 10-valent pneumococcal conjugate vaccine, lower Geometric Mean antibody Concentrations (GMCs) and opsonophagocytic assay (OPA) antibody GMTs were observed for one pneumococcal serotype (18C conjugated to tetanus toxoid carrier protein). The clinical relevance of this observation is unknown. There was no impact of co-administration on immune responses to the other nine pneumococcal serotypes.

One month after co-administration with a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed (Tdap) in subjects aged 9 to 25 years, lower GMCs were observed to each pertussis antigen (pertussis toxoid [PT], filamentous haemagglutinin [FHA] and pertactin [PRN]). More than 98% of subjects had anti-PT, FHA or PRN concentrations above the assay cut-off thresholds. The clinical relevance of these observations is unknown. There was no impact of co-administration on immune responses to ***Nimenrix™*** or the tetanus or diphtheria antigens included in Tdap.

If ***Nimenrix™*** is to be given at the same time as another injectable vaccine, the vaccines should always be administered at different injection sites.

As with other vaccines it may be expected that in patients receiving immunosuppressive treatment, an adequate response may not be elicited.

Pregnancy and lactation

Pregnancy
There is limited experience with use of ***Nimenrix™*** in pregnant women.

Animal studies with ***Nimenrix™*** do not indicate direct or indirect harmful effects with respect to fertility, pregnancy, embryo/foetal development, parturition or post-natal development (see section *Preclinical safety data*).

Nimenrix™ should be used during pregnancy only when clearly needed, and the possible advantages outweigh the potential risks for the foetus.

Lactation
The safety of ***Nimenrix™*** when administered to breast-feeding women has not been evaluated. It is unknown whether ***Nimenrix™*** is excreted in human breast milk.

Nimenrix™ should only be used during breast-feeding when the possible advantages outweigh the potential risks.

Undesirable effects

Summary of safety profile

The safety of ***Nimenrix™*** presented in the table below is based on two clinical study datasets as follows:

- A pooled analysis of data from 9,621 subjects administered a single dose of ***Nimenrix™***. This total included 3,079 toddlers (12 months to 23 months), 909 children between 2 and 5 years of

age, 990 children between 6 and 10 years of age, 2,317 adolescents (11 to 17 years) and 2,326 adults (18 to 55 years).

- Data from a study in infants aged 6 to 12 weeks at the time of the first dose (Study MenACWY-TT-083), 1,052 subjects received at least one dose of a primary series of 2 or 3 doses of ***Nimenrix™*** and 1,008 received a booster dose at approximately 12 months of age.

Safety data have also been evaluated in a separate study, in which a single dose of ***Nimenrix™*** was administered to 274 individuals aged 56 years and older.

Tabulated list of undesirable effects

Undesirable effects reported are listed according to the following frequency:

Very common: ≥1/10
Common: ≥1/100 to <1/10
Uncommon: ≥1/1,000 to <1/100
Rare: ≥1/10,000 to <1/1,000
Very rare: <1/10,000
Not known (cannot be estimated from the available data)

Table 1 shows the undesirable effects reported from the studies in subjects aged from 6 weeks up to 55 years of age and post-marketing experience. Undesirable effects reported in subjects aged >55 years were similar to those observed in younger adults.

Table 1: Tabulated summary of undesirable effects by system organ class

System Organ Class	Frequency	Undesirable effects
Blood and lymphatic system disorders	Not known***	Lymphadenopathy
Metabolism and nutrition disorders	Very common	Appetite lost
Psychiatric disorders	Very common	Irritability
	Uncommon	Insomnia Crying
Nervous system disorders	Very common	Drowsiness Headache
	Uncommon	Hypoaesthesia Dizziness
Gastrointestinal disorders	Common	Diarrhoea Vomiting Nausea*
Skin and subcutaneous tissue disorders	Uncommon	Pruritus Rash**
Musculoskeletal and connective tissue disorders	Uncommon	Myalgia Pain in extremity
General disorders and administration site conditions	Very common	Fever Swelling at injection site Pain at injection site Redness at injection site Fatigue
	Common	Injection site haematoma*
	Uncommon	Malaise Injection site induration Injection site pruritus Injection site warmth

		Injection site anaesthesia
	Not known***	Extensive limb swelling at the injection site, frequently associated with erythema, sometimes involving the adjacent joint or swelling of the entire injected limb

*Nausea and Injection site haematoma occurred at a frequency of Uncommon in infants
**Rash occurred at a frequency of Common in infants
***ADR identified post-marketing

PHARMACOLOGICAL PROPERTIES

Pharmacodynamic properties

Mechanism of action

Anti-capsular meningococcal antibodies protect against meningococcal disease via complement mediated bactericidal killing. ***Nimenrix™*** induces the production of bactericidal antibodies against capsular polysaccharides of *Neisseria meningitidis* serogroups A, C, W-135, and Y when measured by assays using either rSBA or hSBA. By conjugating capsular polysaccharide to a protein carrier that contains T-cell epitopes, meningococcal conjugate vaccines like ***Nimenrix™*** change the nature of immune response to capsular polysaccharide from T-cell independent to T-cell dependent.

Immunogenicity in infants

In Study MenACWY-TT-083, the first dose was administered at 6 to 12 weeks of age, the second after an interval of 2 months, and a third (booster) dose administered at approximately 12 months of age. DTaP-HBV-IPV/Hib and a 10-valent pneumococcal vaccine were co-administered. ***Nimenrix™*** elicited rSBA and hSBA titres against the four meningococcal groups as shown in Table 2. The response against group C was non-inferior to the one elicited by licensed MenC-CRM and MenC-TT vaccines in terms of percentages with rSBA titres ≥8 at 1 month after the second dose.

Data from this study support the extrapolation of the immunogenicity data and posology to infants from 12 weeks to less than 6 months of age.

Table 2: rSBA and hSBA titres following two doses of *Nimenrix*™ (or MenC-CRM or MenC-TT) given 2 months apart with the first dose administered to infants 6-12 weeks of age and following a booster at 12 months of age (Study MenACWY-TT-083)

Meningo-coccal group	Vaccine group	Time point	rSBA*			hSBA**		
			N	≥8 (95% CI)	GMT (95% CI)	N	≥8 (95% CI)	GMT (95% CI)
A	*Nimenrix*™	Post-dose 2[(1)]	456	97.4% (95.4; 98.6)	203 (182; 227)	202	96.5% (93.0; 98.6)	157 (131; 188)
		Post-booster[(1)]	462	99.6% (98.4; 99.9)	1561 (1412; 1725)	214	99.5% (97.4;100)	1007 (836;1214)
C	*Nimenrix*™	Post-dose 2[(1)]	456	98.7% (97.2; 99.5)	612 (540; 693)	218	98.6% (96.0; 99.7)	1308 (1052; 1627)
		Post-booster[(1)]	463	99.8% (98.8; 100)	1177 (1059; 1308)	221	99.5% (97.5; 100)	4992 (4086; 6100)
	MenC-CRM vaccine	Post-dose 2[(1)]	455	99.6% (98.4; 99.9)	958 (850; 1079)	202	100% (98.2; 100)	3188 (2646; 3841)
		Post-booster[(1)]	446	98.4% (96.8; 99.4)	1051 (920; 1202)	216	100% (98.3; 100)	5438 (4412; 6702)
	MenC-TT vaccine	Post-dose 2[(1)]	457	100% (99.2; 100)	1188 (1080; 1307)	226	100% (98.4; 100)	2626 (2219; 3109)
		Post-booster[(1)]	459	100% (99.2; 100)	1960 (1776; 2163)	219	100% (98.3; 100)	5542 (4765; 6446)
W	*Nimenrix*™	Post-dose 2[(1)]	455	99.1% (97.8; 99.8)	1605 (1383; 1862)	217	100% (98.3; 100)	753 (644; 882)
		Post-booster[(1)]	462	99.8% (98.8; 100)	2777 (2485; 3104)	218	100% (98.3; 100)	5123 (4504; 5826)
Y	*Nimenrix*™	Post-dose 2[(1)]	456	98.2% (96.6; 99.2)	483 (419; 558)	214	97.7% (94.6; 99.2)	328 (276; 390)
		Post-booster[(1)]	462	99.4% (99.1; 99.9)	881 (787; 986)	217	100% (98.3; 100)	2954 (2498; 3493)

The analysis of immunogenicity was conducted on the primary according-to-protocol (ATP) cohort.

*rSBA analysis performed at Public Health England (PHE) laboratories in UK

**hSBA analysis performed at GSK laboratories

[(1)] blood sampling performed 21 to 48 days post vaccination

In Study MenACWY-TT-087, infants received either a single primary dose at 6 months followed by a booster dose at 15-18 months or three primary doses at 2, 4, and 6 months followed by a booster dose at 15-18 months. All subjects also received DTaP-IPV/Hib and 10-valent pneumococcal conjugate vaccines at all time points. A single primary dose administered at 6 months of age elicited robust rSBA titres to the four meningococcal groups, as measured by the percentage of subjects with rSBA titres ≥8, that were comparable to responses after the last dose of a three-dose primary series. A booster dose produced robust responses, comparable between the two dosing groups, against all four meningococcal groups. Results are shown in Table 3.

Table 3: rSBA and hSBA titres following a single dose of *Nimenrix*™ in infants at 6 months of age and pre-and post-booster at 15-18 months of age (Study MenACWY-TT-087)

Meningo-coccal group	Time point	rSBA*			hSBA**		
		N	≥8 (95% CI)	GMT (95% CI)	N	≥8 (95% CI)	GMT (95% CI)
A	Post-dose 1[(1)]	163	98.8% (95.6; 99.9)	1333 (1035; 1716)	59	98.3% (90.9; 100)	271 (206; 355)
	Pre-booster	131	81.7% (74; 87.9)	125 (84.4; 186)	71	66.2% (54; 77)	20.8 (13.5; 32.2)
	Post-booster[(1)]	139	99.3% (96.1; 100)	2762 (2310; 3303)	83	100% (95.7; 100)	1416 (1140; 1758)
C	Post-dose 1[(1)]	163	99.4% (96.6; 100)	592 (482; 726)	66	100% (94.6;100)	523 (382; 717)
	Pre-booster	131	65.6% (56.9; 73.7)	27.4 (20.6; 36.6)	78	96.2% (89.2; 99.2)	151 (109; 210)
	Post-booster[(1)]	139	99.3% (96.1; 100)	2525 (2102; 3033)	92	100% (96.1; 100)	13360 (10953; 16296)
W	Post-dose 1[(1)]	163	93.9% (89; 97)	1256 (917; 1720)	47	87.2% (74.3; 95.2)	137 (78.4; 238)
	Pre-booster	131	77.9% (69.8; 84.6)	63.3 (45.6; 87.9)	53	100% (93.3; 100)	429 (328; 559)
	Post-booster[(1)]	139	100% (97.4; 100)	3145 (2637; 3750)	59	100% (93.9; 100)	9016 (7045; 11537)
Y	Post-dose 1[(1)]	163	98.8% (95.6; 99.9)	1470 (1187; 1821)	52	92.3% (81.5; 97.9)	195 (118; 323)
	Pre-booster	131	88.5% (81.8; 93.4)	106 (76.4; 148)	61	98.4% (91.2; 100)	389 (292; 518)
	Post-booster[(1)]	139	100% (97.4; 100)	2749 (2301; 3283)	69	100% (94.8; 100)	5978 (4747; 7528)

The analysis of immunogenicity was conducted on the primary ATP cohort.
*rSBA analysis performed at PHE laboratories in UK
**hSBA analysis performed at Neomed in Canada
[(1)] blood sampling performed 1 month post vaccination

Measurement of hSBA titres was a secondary endpoint in Study MenACWY-TT-087. Although similar responses to groups A and C were observed with both dosing schedules, a single primary dose in infants at 6 months was associated with lower hSBA titres to groups W-135 and Y as measured by the percentage of subjects with hSBA titres ≥8 [87.2% (95% CI: 74.3, 95.2) and 92.3% (95% CI: 81.5, 97.9), respectively] compared with three primary doses at 2, 4, and 6 months of age [100% (95% CI: 96.6, 100) and 100% (95% CI: 97.1, 100), respectively] (see section *Special warnings and precautions for use*). After a booster dose, hSBA titres to all four meningococcal groups were comparable between the two dosing schedules. Results are shown in Table 3.

Immunogenicity in toddlers aged 12-23 months

In clinical studies MenACWY-TT-039 and MenACWY-TT-040, a single dose of ***Nimenrix™*** elicited SBA titres against the four meningococcal groups, with group C rSBA titres that were comparable to those elicited by a licensed MenC-CRM vaccine in terms of the percentage of subjects with rSBA titres ≥8. In Study MenACWY-TT-039, hSBA was also measured as a secondary endpoint. Results are shown in Table 4.

Table 4: SBA* titres following a single dose of *Nimenrix*™ (or MenC-CRM) in toddlers aged 12-23 months (Studies MenACWY-TT-039/040)

Meningo-coccal group	Vaccine group	Study MenACWY-TT-039[(1)]						Study MenACWY-TT-040[(2)]		
		rSBA*			hSBA*			rSBA*		
		N	≥8 (95% CI)	GMT (95% CI)	N	≥8 (95% CI)	GMT (95% CI)	N	≥8 (95% CI)	GMT (95% CI)
A	***Nimenrix*™**	354	99.7% (98.4; 100)	2205 (2008; 2422)	338	77.2% (72.4; 81.6)	19.0 (16.4; 22.1)	183	98.4% (95.3; 99.7)	3170 (2577; 3899)
C	***Nimenrix*™**	354	99.7% (98.4; 100)	478 (437; 522)	341	98.5% (96.6; 99.5)	196 (175; 219)	183	97.3% (93.7; 99.1)	829 (672; 1021)
	MenC-CRM vaccine	121	97.5% (92.9; 99.5)	212 (170; 265)	116	81.9% (73.7; 88.4)	40.3 (29.5; 55.1)	114	98.2% (93.8; 99.8)	691 (521; 918)
W-135	***Nimenrix*™**	354	100% (99.0; 100)	2682 (2453; 2932)	336	87.5% (83.5 ; 90.8)	48.9 (41.2; 58.0)	186	98.4% (95.4; 99.7)	4022 (3269; 4949)
Y	***Nimenrix*™**	354	100% (99.0; 100)	2729 (2473; 3013)	329	79.3% (74.5; 83.6)	30.9 (25.8; 37.1)	185	97.3% (93.8; 99.1)	3168 (2522; 3979)

The analysis of immunogenicity was conducted on the ATP cohorts.
[(1)] blood sampling performed 42 to 56 days post vaccination
[(2)] blood sampling performed 30 to 42 days post vaccination
*SBA analyses performed at GSK laboratories

In Study MenACWY-TT-104, ***Nimenrix™*** elicited rSBA titres against all four meningococcal groups following one or two doses administered 2 months apart that were similar in terms of the percentage of subjects with rSBA titre ≥8 and GMT as shown in Table 5.

Table 5: rSBA and hSBA titres following one or two doses of *Nimenrix*™ with the first dose administered to toddlers aged 12-14 months (Study MenACWY-TT-104)

Meningo-coccal group	*Nimenrix*™ dose group	Time point[(1)]	rSBA*			hSBA**		
			N	≥8 (95% CI)	GMT (95% CI)	N	≥8 (95% CI)	GMT (95% CI)
A	**1 dose**	Post dose 1	180	97.8% (94.4; 99.4)	1437 (1118; 1847)	74	95.9% (88.6; 99.2)	118 (86.8; 161)
	2 doses	Post dose 1	158	96.8% (92.8; 99.0)	1275 (970; 1675)	66	97.0% (89.5; 99.6)	133 (98.1; 180)
		Post dose 2	150	98.0% (94.3; 99.6)	1176 (922; 1501)	66	97.0% (89.5; 99.6)	170 (126; 230)
C	**1 dose**	Post dose 1	179	95.0% (90.7; 97.7)	452 (346; 592)	78	98.7% (93.1; 100)	152 (105; 220)
	2 doses	Post dose 1	157	95.5% (91.0; 98.2)	369 (281; 485)	70	95.7% (88.0; 99.1)	161 (110; 236)
		Post dose 2	150	98.7% (95.3; 99.8)	639 (522; 783)	69	100% (94.8; 100)	1753 (1278; 2404)

Meningo-coccal group	*Nimenrix* ™ dose group	Time point[(1)]	rSBA*			hSBA**		
			N	≥8 (95% CI)	GMT (95% CI)	N	≥8 (95% CI)	GMT (95% CI)
W-135	1 dose	Post dose 1	180	95.0% (90.8; 97.7)	2120 (1601; 2808)	72	62.5% (50.3; 73.6)	27.5 (16.1; 46.8)
	2 doses	Post dose 1	158	94.9% (90.3; 97.8)	2030 (1511; 2728)	61	68.9% (55.7; 80.1)	26.2 (16.0; 43.0)
		Post dose 2	150	100% (97.6; 100)	3533 (2914; 4283)	70	97.1% (90.1; 99.7)	757 (550; 1041)
Y	1 dose	Post dose 1	180	92.8% (88.0; 96.1)	952 (705; 1285)	71	67.6% (55.5; 78.2)	41.2 (23.7; 71.5)
	2 doses	Post dose 1	157	93.6% (88.6; 96.9)	933 (692; 1258)	56	64.3% (50.4; 76.6)	31.9 (17.6; 57.9)
		Post dose 2	150	99.3% (96.3; 100)	1134 (944; 1360)	64	95.3% (86.9; 99.0)	513 (339; 775)

The analysis of immunogenicity was conducted on the ATP cohort.
(1) blood sampling performed 21 to 48 days post vaccination
*rSBA analysis performed at PHE laboratories
**hSBA analysis performed at GSK laboratories

In Study MenACWY-TT-104, hSBA titres were measured as a secondary endpoint. ***Nimenrix™*** elicited hSBA titres against groups W-135 and Y that were higher in terms of the percentage of subjects with hSBA titre ≥8 when two doses were given compared with one (see section *Special warnings and precautions for use*). ***Nimenrix™*** elicited hSBA titres against groups A and C that were similar in terms of the percentage of subjects with hSBA titre ≥8 when two doses were given compared with one. Results are shown in Table 5.

rSBA and hSBA titres were determined over a period of 10 years in children initially vaccinated with one dose of ***Nimenrix™*** or MenC-CRM at 12 to 23 months of age in Study MenACWY-TT-027. Persistence of SBA titres was evaluated in two extension studies: MenACWY-TT-032 (up to 5 years) and MenACWY-TT-100 (up to 10 years). Study MenACWY-TT-100 also evaluated the response to a single booster dose of ***Nimenrix™*** administered 10 years following the initial vaccination with ***Nimenrix™*** or MenC-CRM. Results are shown in Table 6 (see section *Special warnings and precautions for use*).

Table 6: rSBA and hSBA titres following a single dose of *Nimenrix*™ (or MenC-CRM) in toddlers aged 12-23 months, persistence up to 10 years, and post-booster administered 10 years following initial vaccination (Studies MenACWY-TT-027/032/100)

Meningo coccal group	Vaccine group	Time point	rSBA*			hSBA**		
			N	≥8 (95% CI)	GMT (95% CI)	N	≥8 (95% CI)	GMT (95% CI)
A	*Nimenrix* ™	Month 1[(1)]	222	100% (98.4; 100)	3707 (3327; 4129)	217	91.2% (86.7; 94.6)	59.0 (49.3; 70.6)
		Year 4[(2)]	45	64.4% (48.8; 78.1)	35.1 (19.4; 63.4)	44	52.3% (36.7; 67.5)	8.8 (5.4; 14.2)
		Year 5[(2)]	49	73.5% (58.9; 85.1)	37.4 (22.1; 63.2)	45	35.6% (21.9: 51.2)	5.2 (3.4; 7.8)
		Year 10[(3)] (Pre-booster)	62	66.1% (53.0; 77.7)	28.9 (16.4; 51.0)	59	25.4% (15.0; 38.4)	4.2 (3.0; 5.9)

Table 6: rSBA and hSBA titres following a single dose of *Nimenrix*™ (or MenC-CRM) in toddlers aged 12-23 months, persistence up to 10 years, and post-booster administered 10 years following initial vaccination (Studies MenACWY-TT-027/032/100)

Meningococcal group	Vaccine group	Time point	rSBA*			hSBA**		
			N	≥8 (95% CI)	GMT (95% CI)	N	≥8 (95% CI)	GMT (95% CI)
		(Post-booster)[3,4]	62	98.4% (91.3; 100)	5122 (3726; 7043)	62	100% (94.2; 100)	1534 (1112; 2117)
C	*Nimenrix*™	Month 1[1]	220	100% (98.3; 100)	879 (779; 991)	221	99.1% (96.8; 99.9)	190 (165; 219)
		Year 4[2]	45	97.8% (88.2; 99.9)	110 (62.7; 192)	45	97.8% (88.2; 99.9)	370 (214; 640)
		Year 5[2]	49	77.6% (63.4; 88.2)	48.9 (28.5; 84.0)	48	91.7% (80.0; 97.7)	216 (124; 379)
		Year 10[3] (Pre-booster)	62	82.3% (70.5; 90.8)	128 (71.1; 231)	60	91.7% (81.6; 97.2)	349 (197; 619)
		(Post-booster)[3,4]	62	100% (94.2; 100)	7164 (5478; 9368)	59	100% (93.9; 100)	33960 (23890; 48274)
	MenC-CRM vaccine	Month 1[1]	68	98.5% (92.1; 100)	415 (297; 580)	68	72.1% (59.9; 82.3)	21.2 (13.9; 32.3)
		Year 4[2]	10	80.0% (44.4; 97.5)	137 (22.6; 832)	10	70.0% (34.8; 93.3)	91.9 (9.8; 859)
		Year 5[2]	11	63.6% (30.8; 89.1)	26.5 (6.5; 107)	11	90.9% (58.7; 99.8)	109 (21.2; 557)
		Year 10[3] (Pre-booster)	16	87.5% (61.7; 98.4)	86.7 (29.0; 259)	15	93.3% (68.1; 99.8)	117 (40.0; 344)
		(Post-booster)[3,4]	16	100% (79.4; 100)	5793 (3631; 9242)	15	100% (78.2; 100)	42559 (20106; 90086)
W-135	*Nimenrix*™	Month 1[1]	222	100% (98.4; 100)	5395 (4870; 5976)	177	79.7% (73.0; 85.3)	38.8 (29.7; 50.6)
		Year 4[2]	45	60.0% (44.3; 74.3)	50.8 (24.0; 108)	45	84.4% (70.5; 93.5)	76.9 (44.0; 134)
		Year 5[2]	49	34.7% (21.7; 49.6)	18.2 (9.3; 35.3)	46	82.6% (68.6; 92.2)	59.7 (35.1; 101)
		Year 10[3] (Pre-booster)	62	30.6% (19.6; 43.7)	15.8 (9.1; 27.6)	52	44.2% (30.5; 58.7)	7.7 (4.9; 12.2)
		(Post-booster)[3,4]	62	100% (94.2; 100)	25911 (19120; 35115)	62	100% (94.2; 100)	11925 (8716; 16316)
Y	*Nimenrix*™	Month 1[1]	222	100% (98.4; 100)	2824 (2529; 3153)	201	66.7% (59.7; 73.1)	24.4 (18.6; 32.1)
		Year 4[2]	45	62.2% (46.5; 76.2)	44.9 (22.6; 89.3)	41	87.8% (73.8; 95.9)	74.6 (44.5; 125)
		Year 5[2]	49	42.9% (28.8; 57.8)	20.6 (10.9; 39.2)	45	80.0% (65.4; 90.4)	70.6 (38.7; 129)
		Year 10[3] (Pre-booster)	62	45.2% (32.5; 58.3)	27.4 (14.7; 51.0)	56	42.9% (29.7; 56.8)	9.1 (5.5; 15.1)
		(Post-booster)[3,4]	62	98.4% (91.3; 100)	7661 (5263; 11150)	61	100% (94.1; 100)	12154 (9661; 15291)

The analysis of immunogenicity was conducted on the ATP cohorts for 1 month and 5 years post vaccination and the booster ATP cohort. Subjects with a suboptimal response to meningococcal group C (defined as SBA titre below the pre-defined assay cut-off) were to receive an additional dose of MenC vaccine before Year 6. These subjects were excluded from the analysis at Years 4 and 5 but included in the analysis at Year 10.

(1) Study MenACWY-TT-027
(2) Study MenACWY-TT-032
(3) Study MenACWY-TT-100
(4) Blood sampling was performed 1 month after a booster dose at Year 10.

*rSBA analysis performed at GSK laboratories for 1 month post primary vaccination samples and at PHE laboratories in UK for subsequent sampling time points.

**hSBA analysis performed at GSK laboratories and at Neomed in Canada for time points in Study MenACWY-TT-100.

Persistence of booster response
Study MenACWY-TT-102 evaluated the persistence of SBA titres up to 6 years after a booster dose of ***Nimenrix™*** or MenC-CRM$_{197}$ administered in Study MenACWY-TT-048 to children who initially received the same vaccine at 12 to 23 months of age in Study MenACWY-TT-039. A single booster dose was administered 4 years after the initial vaccination. Results are shown in Table 7 (see section *Special warnings and precautions for use*).

Table 7: rSBA and hSBA titres following a single dose of *Nimenrix*™ (or MenC-CRM) in toddlers aged 12-23 months, persistence at 4 years and response following a booster 4 years after initial vaccination, and persistence up to 6 years following booster vaccination (Studies MenACWY-TT-039/048/102)

Meningo-coccal group	Vaccine group	Time point	rSBA*			hSBA**		
			N	≥8 (95% CI)	GMT (95% CI)	N	≥8 (95% CI)	GMT (95% CI)
A	*Nimenrix*™	Month 1[1]	354	99.7% (98.4; 100)	2205 (2008; 2422)	338	77.2% (72.4; 81.6)	19.0 (16.4; 22.1)
		Year 4[2] (Pre-*Nimenrix*™ booster)	212	74.5% (68.1; 80.2)	112 (80.3; 156)	187	28.9% (22.5; 35.9)	4.8 (3.9; 5.9)
		(Post-booster)[2,3]	214	100% (98.3; 100)	7173 (6389; 8054)	202	99.5% (97.3; 100)	1343 (1119; 1612)
		5 years after booster dose[4]	137	89.8% (83.4; 94.3)	229 (163; 322)	135	53.3% (44.6; 62.0)	13.2 (9.6; 18.3)
		6 years after booster dose[4]	134	92.5% (86.7; 96.4)	297 (214; 413)	130	58.5% (49.5; 67.0)	14.4 (10.5; 19.7)
C	*Nimenrix*™	Month 1[1]	354	99.7% (98.4; 100)	478 (437; 522)	341	98.5% (96.6; 99.5)	196 (175; 219)
		Year 4[2] (Pre-*Nimenrix*™ booster)	213	39.9% (33.3; 46.8)	12.1 (9.6; 15.2)	200	73.0% (66.3; 79.0)	31.2 (23.0; 42.2)
		(Post-booster)[2,3]	215	100% (98.3; 100)	4512 (3936; 5172)	209	100% (98.3; 100)	15831 (13626; 18394)
		5 years after booster dose[4]	137	80.3% (72.6; 86.6)	66.0 (48.1; 90.5)	136	99.3% (96.0; 100)	337 (261; 435)
		6 years after booster dose[4]	134	71.6% (63.2; 79.1)	39.6 (28.6; 54.6)	130	97.7% (93.4; 99.5)	259 (195; 345)
	MenC-CRM vaccine	Month 1[1]	121	97.5% (92.9; 99.5)	212 (170; 265)	116	81.9% (73.7; 88.4)	40.3 (29.5; 55.1)
		Year 4[2] (Pre-MenC-CRM$_{197}$ booster)	43	37.2% (23.0; 53.3)	14.3 (7.7; 26.5)	31	48.4% (30.2; 66.9)	11.9 (5.1; 27.6)
		(Post-booster)[2,3]	43	100% (91.8; 100)	3718 (2596; 5326)	33	100% (89.4; 100)	8646 (5887; 12699)
		5 years after booster dose[4]	23	78.3% (56.3; 92.5)	47.3 (19.0; 118)	23	100% (85.2; 100)	241 (139; 420)
		6 years after booster dose[4]	23	65.2% (42.7; 83.6)	33.0 (14.7; 74.2)	23	95.7% (78.1; 99.9)	169 (94.1; 305)
W-135	*Nimenrix*™	Month 1[1]	354	100% (99.0; 100)	2682 (2453; 2932)	336	87.5% (83.5; 90.8)	48.9 (41.2; 58.0)
		Year 4[2] (Pre-*Nimenrix*™ booster)	213	48.8% (41.9; 55.7)	30.2 (21.9; 41.5)	158	81.6% (74.7; 87.3)	48.3 (36.5; 63.9)

Table 7: rSBA and hSBA titres following a single dose of *Nimenrix*™ (or MenC-CRM) in toddlers aged 12-23 months, persistence at 4 years and response following a booster 4 years after initial vaccination, and persistence up to 6 years following booster vaccination (Studies MenACWY-TT-039/048/102)

Meningo-coccal group	Vaccine group	Time point	rSBA*			hSBA**		
			N	≥8 (95% CI)	GMT (95% CI)	N	≥8 (95% CI)	GMT (95% CI)
		(Post-booster)[2,3]	215	100% (98.3; 100)	10950 (9531; 12579)	192	100% (98.1; 100)	14411 (12972; 16010)
		5 years after booster dose[4]	137	88.3% (81.7; 93.2)	184 (130; 261)	136	100% (97.3; 100)	327 (276; 388)
		6 years after booster dose[4]	134	85.8% (78.7; 91.2)	172 (118; 251)	133	98.5% (94.7; 99.8)	314 (255; 388)
Y	*Nimenrix*™	Month 1[1]	354	100% (99.0; 100)	2729 (2473; 3013)	329	79.3% (74.5; 83.6)	30.9 (25.8; 37.1)
		Year 4[2] (Pre-*Nimenrix*™ booster)	213	58.2% (51.3; 64.9)	37.3 (27.6; 50.4)	123	65.9% (56.8; 74.2)	30.2 (20.2; 45.0)
		(Post-booster)[2,3]	215	100% (98.3; 100)	4585 (4129; 5093)	173	100% (97.9; 100)	6776 (5961; 7701)
		5 years after booster dose[4]	137	92.7% (87.0; 96.4)	265 (191; 368)	137	97.8% (93.7; 99.5)	399 (321; 495)
		6 years after booster dose[4]	134	94.0% (88.6; 97.4)	260 (189; 359)	131	97.7% (93.5; 99.5)	316 (253; 394)

The analysis of immunogenicity was conducted on the ATP cohort for each time point.

(1) Study MenACWY-TT-039
(2) Study MenACWY-TT-048
(3) Blood sampling was performed 1 month after a booster dose at Year 4.
(4) Study MenACWY-TT-102

*rSBA analysis performed at GSK laboratories for 1 month post primary vaccination samples and at PHE laboratories in UK for the subsequent sampling time points.
**hSBA analysis performed at GSK laboratories and at Neomed in Canada for time points in Study MenACWY-TT-102.

Immunogenicity in children aged 2-10 years

In Study MenACWY-TT-081, a single dose of ***Nimenrix*™** was demonstrated to be non-inferior to another licensed MenC-CRM vaccine in terms of vaccine response to group C [94.8% (95% CI: 91.4; 97.1) and 95.7% (95% CI: 89.2; 98.8), respectively]. The GMT was lower for the ***Nimenrix*™** group [2795 (95% CI: 2393; 3263)] versus the MenC-CRM vaccine [5292 (95% CI: 3815; 7340)].

In Study MenACWY-TT-038, a single dose of ***Nimenrix*™** was demonstrated to be non-inferior to the licensed ACWY-PS vaccine in terms of vaccine response to the four meningococcal groups as shown in Table 8.

Table 8: rSBA* titres following a single dose of *Nimenrix*™ (or ACWY-PS) in children aged 2-10 years (Study MenACWY-TT-038)

Meningo-coccal group	*Nimenrix*™[1]			ACWY-PS vaccine[1]		
	N	VR (95% CI)	GMT (95% CI)	N	VR (95% CI)	GMT (95% CI)
A	594	89.1% (86.3 91.5)	6343 (5998; 6708)	192	64.6% (57.4; 71.3)	2283 (2023; 2577)
C	691	96.1% (94.4; 97.4)	4813 (4342; 5335)	234	89.7% (85.1; 93.3)	1317 (1043; 1663)
W-135	691	97.4% (95.9; 98.4)	11543 (10873; 12255)	236	82.6% (77.2; 87.2)	2158 (1815; 2565)

Meningo-coccal group	*Nimenrix*™[1]			ACWY-PS vaccine[1]		
	N	VR (95% CI)	GMT (95% CI)	N	VR (95% CI)	GMT (95% CI)
Y	723	92.7% (90.5; 94.5)	10825 (10233; 11452)	240	68.8% (62.5; 74.6)	2613 (2237; 3052)

The analysis of immunogenicity was conducted on the ATP cohort.
[1] Blood sampling performed 1 month post vaccination.
VR: vaccine response defined as the proportion of subjects with:
- rSBA titres ≥32 for initially seronegative subjects (i.e., pre-vaccination rSBA titre <8)
- at least a 4-fold increase in rSBA titres from pre- to post-vaccination for initially seropositive subjects (i.e., pre-vaccination rSBA titre ≥8)

*rSBA analysis performed at GSK laboratories

Persistence of SBA titres was evaluated in children initially vaccinated in Study MenACWY-TT-081 as shown in Table 9 (see section *Special warnings and precautions for use*).

Table 9: rSBA and hSBA titres up to 44 months following *Nimenrix*™ (or MenC-CRM) in children aged 2-10 years at time of vaccination (Study MenACWY-TT-088)

Meningo coccal group	Vaccine group	Time point (months)	rSBA*			hSBA**		
			N	≥8 (95% CI)	GMT (95% CI)	N	≥8 (95% CI)	GMT (95% CI)
A	*Nimenrix*™	32	193	86.5% (80.9; 91.0)	196 (144; 267)	90	25.6% (16.9; 35.8)	4.6 (3.3; 6.3)
		44	189	85.7% (79.9; 90.4)	307 (224; 423)	89	25.8% (17.1; 36.2)	4.8 (3.4; 6.7)
C	*Nimenrix*™	32	192	64.6% (57.4; 71.3)	34.8 (26.0; 46.4)	90	95.6% (89.0; 98.8)	75.9 (53.4; 108)
		44	189	37.0% (30.1; 44.3)	14.5 (10.9; 19.2)	82	76.8% (66.2; 85.4)	36.4 (23.1; 57.2)
	MenC-CRM vaccine	32	69	76.8% (65.1; 86.1)	86.5 (47.3; 158)	33	90.9% (75.7; 98.1)	82.2 (34.6; 196)
		44	66	45.5% (33.1; 58.2)	31.0 (16.6; 58.0)	31	64.5% (45.4; 80.8)	38.8 (13.3; 113)
W-135	*Nimenrix*™	32	193	77.2% (70.6; 82.9)	214 (149; 307)	86	84.9% (75.5; 91.7)	69.9 (48.2; 101)
		44	189	68.3% (61.1; 74.8)	103 (72.5; 148)	87	80.5% (70.6; 88.2)	64.3 (42.7; 96.8)
Y	*Nimenrix*™	32	193	81.3% (75.1; 86.6)	227 (165; 314)	91	81.3% (71.8; 88.7)	79.2 (52.5; 119)
		44	189	62.4% (55.1; 69.4)	78.9 (54.6; 114)	76	82.9% (72.5; 90.6)	127 (78.0; 206)

The analysis of immunogenicity was conducted on the ATP cohort for persistence adapted for each time point.
*rSBA analysis performed at PHE laboratories in UK
** hSBA analysis performed at GSK laboratories

Persistence of hSBA titres was evaluated 1 year after vaccination in children aged 6-10 years who were initially vaccinated in Study MenACWY-TT-027 (Table 10) (see section *Special warnings and precautions for use*).

Table 10: hSBA* titres following a single dose of *Nimenrix*™ (or ACWY-PS) in children aged 6-10 years and persistence 1 year following vaccination (Studies MenACWY-TT-027/028)

Meningococcal group	Vaccine group	1 month post-vaccination (Study MenACWY-TT-027)			1 year persistence (Study MenACWY-TT-028)		
		N	≥8 (95% CI)	GMT (95% CI)	N	≥8 (95% CI)	GMT (95% CI)
A	*Nimenrix*™	105	80.0 % (71.1; 87.2)	53.4 (37.3; 76.2)	104	16.3% (9.8; 24.9)	3.5 (2.7; 4.4)
	ACWY-PS vaccine	35	25.7% (12.5; 43.3)	4.1 (2.6; 6.5)	35	5.7% (0.7; 19.2)	2.5 (1.9; 3.3)
C	*Nimenrix*™	101	89.1% (81.3; 94.4)	156 (99.3; 244)	105	95.2% (89.2; 98.4)	129 (95.4; 176)
	ACWY-PS vaccine	38	39.5% (24.0; 56.6)	13.1 (5.4; 32.0)	31	32.3% (16.7; 51.4)	7.7 (3.5; 17.3)
W-135	*Nimenrix*™	103	95.1% (89.0; 98.4)	133 (99.9; 178)	103	100% (96.5; 100)	257 (218; 302)
	ACWY-PS vaccine	35	34.3% (19.1; 52.2)	5.8 (3.3; 9.9)	31	12.9% (3.6; 29.8)	3.4 (2.0; 5.8)
Y	*Nimenrix*™	89	83.1% (73.7; 90.2)	95.1 (62.4; 145)	106	99.1% (94.9; 100)	265 (213; 330)
	ACWY-PS vaccine	32	43.8% (26.4; 62.3)	12.5 (5.6; 27.7)	36	33.3% (18.6; 51.0)	9.3 (4.3; 19.9)

The analysis of immunogenicity was conducted on the ATP cohort for persistence at Year 1.
hSBA analysis was not performed for children aged 2 to <6 years (at time of vaccination).
*hSBA analysis performed at GSK laboratories

SBA titres were determined over a period of 10 years in children initially vaccinated with one dose of ***Nimenrix*™** or ACWY-PS at 2 to 10 years of age in Study MenACWY-TT-027. Persistence of SBA titres was evaluated in two extension studies: MenACWY-TT-032 (up to 5 years) and MenACWY-TT-100 (up to 10 years). Study MenACWY-TT-100 also evaluated the response to a single booster dose of ***Nimenrix*™** administered 10 years following the initial vaccination with ***Nimenrix*™** or ACWY-PS. Results are shown in Table 11 (see section *Special warnings and precautions for use*).

Table 11: rSBA and hSBA titres following a single dose of *Nimenrix*™ (or ACWY-PS) in children aged 2-10 years, persistence up to 10 years, and post-booster administered 10 years following initial vaccination (Studies MenACWY-TT-027/032/100)

Meningococcal group	Vaccine group	Time point	rSBA*			hSBA**		
			N	≥8 (95% CI)	GMT (95% CI)	N	≥8 (95% CI)	GMT (95% CI)
A	*Nimenrix*™	Month 1[(1)]	225	100% (98.4; 100)	7301 (6586; 8093)	111[(5)]	81.1% (72.5; 87.9)	57.0 (40.3; 80.6)
		Year 5[(2)]	98	90.8% (83.3; 95.7)	141 (98.2; 203)	n/a[(6)]	--	--
		Year 6[(3)]	98	79.6% (70.3; 87.1)	107 (66.0; 174)	90	41.1% (30.8; 52.0)	6.5 (4.8; 8.8)
		Year 10[(3)] (Pre-booster)	73	89.0% (79.5; 95.1)	96.3 (57.1; 163)	62	33.9% (22.3; 47.0)	4.5 (3.3; 6.2)
		(Post-booster)[(3,4)]	74	95.9% (88.6; 99.2)	4626 (3041; 7039)	73	100% (95.1; 100)	1213 (994; 1481)
	ACWY-PS vaccine	Month 1[(1)]	75	100% (95.2; 100)	2033 (1667; 2480)	35[(5)]	25.7% (12.5; 43.3)	4.1 (2.6; 6.5)
		Year 5[(2)]	13	15.4% (1.9; 45.4)	4.7 (3.7; 6.0)	n/a[(6)]	--	--
		Year 6[(3)]	24	12.5% (2.7; 32.4)	5.8 (3.5; 9.6)	21	33.3% (14.6; 57.0)	5.9 (3.0; 11.7)

Table 11: rSBA and hSBA titres following a single dose of *Nimenrix*™ (or ACWY-PS) in children aged 2-10 years, persistence up to 10 years, and post-booster administered 10 years following initial vaccination (Studies MenACWY-TT-027/032/100)

Meningo-coccal group	Vaccine group	Time point	rSBA*			hSBA**		
			N	≥8 (95% CI)	GMT (95% CI)	N	≥8 (95% CI)	GMT (95% CI)
		Year 10[3] (Pre-booster)	17	23.5% (6.8; 49.9)	8.0 (3.3; 19.3)	17	29.4% (10.3; 56.0)	6.2 (2.4; 15.7)
		(Post-booster)[3,4]	17	100% (80.5; 100)	6414 (3879; 10608)	17	100% (80.5; 100)	211 (131; 340)
C	*Nimenrix*™	Month 1[1]	225	100% (98.4; 100)	2435 (2106; 2816)	107[5]	89.7% (82.3; 94.8)	155 (101; 237)
		Year 5[2]	98	90.8% (83.3; 95.7)	79.7 (56.0; 113)	n/a[6]	--	--
		Year 6[3]	98	82.7% (73.7; 89.6)	193 (121; 308)	97	93.8% (87.0; 97.7)	427 (261; 700)
		Year 10[3] (Pre-booster)	74	85.1% (75.0; 92.3)	181 (106; 310)	73	91.8% (83.0; 96.9)	222 (129; 380)
		(Post-booster)[3,4]	74	100% (95.1; 100)	4020 (3319; 4869)	71	100% (94.9; 100)	15544 (11735; 20588)
	ACWY-PS vaccine	Month 1[1]	74	100% (95.1; 100)	750 (555; 1014)	38[5]	39.5% (24.0; 56.6)	13.1 (5.4; 32.0)
		Year 5[2]	13	100% (75.3; 100)	128 (56.4; 291)	n/a[6]	--	--
		Year 6[3]	24	79.2% (57.8; 92.9)	98.7 (42.2; 231)	24	100% (85.8; 100)	235 (122; 451)
		Year 10[3] (Pre-booster)	17	76.5% (50.1; 93.2)	96.2 (28.9; 320)	17	100% (80.5; 100)	99.1 (35.8; 274)
		(Post-booster)[3,4]	17	100% (80.5; 100)	15101 (7099; 32122)	17	94.1 (71.3; 99.9)	44794 (10112; 198440)
W-135	*Nimenrix*™	Month 1[1]	225	100% (98.4; 100)	11777 (10666; 13004)	107[5]	95.3% (89.4; 98.5)	134 (101; 178)
		Year 5[2]	98	78.6% (69.1; 86.2)	209 (128; 340)	n/a[6]	--	--
		Year 6[3]	98	73.5% (63.6; 81.9)	265 (155; 454)	92	81.5% (72.1; 88.9)	62.5 (42.0; 93.1)
		Year 10[3] (Pre-booster)	74	68.9% (57.1; 79.2)	206 (109; 392)	59	61.0% (47.4; 73.5)	17.5 (10.5; 29.2)
		(Post-booster)[3,4]	74	100% (95.1; 100)	27944 (22214; 35153)	74	100% (95.1; 100)	6965 (5274; 9198)
	ACWY-PS vaccine	Month 1[1]	75	100% (95.2; 100)	2186 (1723; 2774)	35[5]	34.3% (19.1; 52.2)	5.8 (3.3, 9.9)
		Year 5[2]	13	0% (0.0; 24.7)	4.0 (4.0; 4.0)	n/a[6]	--	--
		Year 6[3]	24	12.5% (2.7; 32.4)	7.6 (3.7; 15.6)	23	30.4% (13.2; 52.9)	7.0 (2.9; 16.9)
		Year 10[3] (Pre-booster)	17	23.5% (6.8; 49.9)	15.4 (4.2; 56.4)	15	26.7% (7.8; 55.1)	4.1 (2.0; 8.5)
		(Post-booster)[3,4]	17	94.1% (71.3; 99.9)	10463 (3254; 33646)	15	100% (78.2; 100)	200 (101; 395)

Table 11: rSBA and hSBA titres following a single dose of *Nimenrix*™ (or ACWY-PS) in children aged 2-10 years, persistence up to 10 years, and post-booster administered 10 years following initial vaccination (Studies MenACWY-TT-027/032/100)

Meningo-coccal group	Vaccine group	Time point	rSBA*			hSBA**		
			N	≥8 (95% CI)	GMT (95% CI)	N	≥8 (95% CI)	GMT (95% CI)
Y	*Nimenrix*™	Month 1[(1)]	225	100% (98.4; 100)	6641 (6044; 7297)	94[(5)]	83.0% (73.8; 89.9)	93.7 (62.1; 141)
		Year 5[(2)]	98	78.6% (69.1; 86.2)	143 (88.0; 233)	n/a[(6)]	--	--
		Year 6[(3)]	98	71.4% (61.4; 80.1)	136 (82.6; 225)	89	65.2% (54.3; 75.0)	40.3 (23.9; 68.1)
		Year 10[(3)] (Pre-booster)	74	67.6% (55.7; 78.0)	98.5 (54.3; 179)	65	72.3% (59.8; 82.7)	35.7 (21.0; 60.6)
		(Post-booster)[(3,4)]	74	100% (95.1; 100)	7530 (5828; 9729)	74	100% (95.1; 100)	11127 (8909; 13898)
	ACWY-PS vaccine	Month 1[(1)]	75	100% (95.2; 100)	1410 (1086; 1831)	32[(5)]	43.8% (26.4; 62.3)	12.5 (5.6; 27.7)
		Year 5[(2)]	13	7.7% (0.2; 36.0)	5.5 (2.7; 11.1)	n/a[(6)]	--	--
		Year 6[(3)]	24	20.8% (7.1; 42.2)	11.6 (4.7; 28.7)	24	25.0% (9.8; 46.7)	7.3 (2.7; 19.8)
		Year 10[(3)] (Pre-booster)	17	17.6% (3.8; 43.4)	10.2 (3.5; 30.2)	14	35.7% (12.8; 64.9)	7.8 (2.5; 24.4)
		(Post-booster)[(3,4)]	17	100% (80.5; 100)	6959 (3637; 13317)	17	100% (80.5; 100)	454 (215; 960)

The analysis of immunogenicity was conducted on the ATP cohort for each time point. Subjects with a suboptimal response to meningococcal group C (defined as SBA titre below the pre-defined assay cut-off) were to receive an additional dose of MenC vaccine before Year 6. These subjects were excluded from the analysis at Year 5 but included in the analyses at Years 6 and 10.

(1) Study MenACWY-TT-027
(2) Study MenACWY-TT-032
(3) Study MenACWY-TT-100
(4) Blood sampling was performed 1 month after a booster dose at Year 10.
(5) Includes children aged 6 to <11 years. hSBA analysis was not performed for children aged 2 to <6 years (at time of vaccination).
(6) Per the protocol for Study MenACWY-TT-032, hSBA was not measured for this age group at Year 5.

*rSBA analysis performed at GSK laboratories for 1 month post primary vaccination samples and at PHE laboratories in UK for subsequent sampling time points.
**hSBA analysis performed at GSK laboratories and at Neomed in Canada for time points in Study MenACWY-TT-100.

Immunogenicity in adolescents aged 11-17 years and adults aged ≥18 years

In two clinical studies, conducted in adolescents aged 11-17 years (Study MenACWY-TT-036) and in adults aged 18-55 years (Study MenACWY-TT-035), either one dose of ***Nimenrix*™** or one dose of the ACWY-PS vaccine was administered.

***Nimenrix*™** was demonstrated to be immunologically non-inferior to the ACWY-PS vaccine in terms of vaccine response as shown in Table 12.

Table12: rSBA* titres following a single dose of *Nimenrix*™ (or ACWY-PS) in adolescents aged 11-17 years and adults aged 18-55 years (Studies MenACWY-TT-035/036)

Meningo-coccal group	Vaccine group	Study MenACWY-TT-036 (11-17 years)[1]			Study MenACWY-TT-035 (18-55 years)[1]		
		N	VR (95% CI)	GMT (95% CI)	N	VR (95% CI)	GMT (95% CI)
A	*Nimenrix*™	553	85.4% (82.1; 88.2)	5928 (5557; 6324)	743	80.1% (77.0; 82.9)	3625 (3372; 3897)
	ACWY-PS vaccine	191	77.5% (70.9; 83.2)	2947 (2612; 3326)	252	69.8% (63.8; 75.4)	2127 (1909; 2370)
C	*Nimenrix*™	642	97.4% (95.8; 98.5)	13110 (11939; 14395)	849	91.5% (89.4; 93.3)	8866 (8011; 9812)
	ACWY-PS vaccine	211	96.7% (93.3; 98.7)	8222 (6807; 9930)	288	92.0% (88.3; 94.9)	7371 (6297; 8628)
W-135	*Nimenrix*™	639	96.4% (94.6; 97.7)	8247 (7639; 8903)	860	90.2% (88.1; 92.1)	5136 (4699; 5614)
	ACWY-PS vaccine	216	87.5% (82.3; 91.6)	2633 (2299; 3014)	283	85.5% (80.9; 89.4)	2461 (2081; 2911)
Y	*Nimenrix*™	657	93.8% (91.6; 95.5)	14086 (13168; 15069)	862	87.0% (84.6; 89.2)	7711 (7100; 8374)
	ACWY-PS vaccine	219	78.5% (72.5; 83.8)	5066 (4463; 5751)	288	78.8% (73.6; 83.4)	4314 (3782; 4921)

The analysis of immunogenicity was conducted on the ATP cohorts.

(1) Blood sampling performed 1 month post vaccination

VR: vaccine response defined as the proportion of subjects with:

- rSBA titres ≥32 for initially seronegative subjects (i.e., pre-vaccination rSBA titre <8)
- at least a 4-fold increase in rSBA titres from pre- to post-vaccination for initially seropositive subjects (i.e., pre-vaccination rSBA titre ≥8)

*rSBA analysis performed at GSK laboratories

rSBA titres were determined over a period of 10 years in subjects initially vaccinated with one dose of ***Nimenrix*™** or ACWY-PS at 11 to 17 years of age in Study MenACWY-TT-036. Persistence of rSBA titres was evaluated in two extension studies: MenACWY-TT-043 (up to 5 years) and MenACWY-TT-101 (at 10 years). Study MenACWY-TT-101 also evaluated the response to a single booster dose of ***Nimenrix*™** administered 10 years following the initial vaccination with ***Nimenrix*™** or ACWY-PS. Results are shown in Table 13.

Table 13: rSBA* titres following a single dose of *Nimenrix*™ (or ACWY-PS) in adolescents aged 11-17 years, persistence up to 10 years, and post-booster administered 10 years following initial vaccination (Studies MenACWY-TT-036/043/101)

Meningo-coccal group	Time point	*Nimenrix*™			ACWY-PS vaccine		
		N	≥8 (95% CI)	GMT (95% CI)	N	≥8 (95% CI)	GMT (95% CI)
A	Month 1[1]	674	100% (99.5; 100)	5929 (5557; 6324)	224	99.6% (97.5; 100)	2947 (2612; 3326)
	Year 3[2]	449	92.9% (90.1; 95.1)	448 (381; 527)	150	82.7% (75.6; 88.4)	206 (147; 288)
	Year 5[2]	236	97.5% (94.5; 99.1)	644 (531; 781)	86	93.0% (85.4; 97.4)	296 (202; 433)
	Year 10[3] (Pre-booster)	162	85.2% (78.8; 90.3)	248 (181; 340)	51	80.4% (66.9; 90.2)	143 (80.5; 253)
	(Post-booster)[3,4]	162	100% (97.7; 100)	3760 (3268; 4326)	51	100% (93.0; 100)	2956 (2041; 4282)

Table 13: rSBA* titres following a single dose of *Nimenrix*™ (or ACWY-PS) in adolescents aged 11-17 years, persistence up to 10 years, and post-booster administered 10 years following initial vaccination (Studies MenACWY-TT-036/043/101)

Meningo-coccal group	Time point	*Nimenrix*™			ACWY-PS vaccine		
		N	≥8 (95% CI)	GMT (95% CI)	N	≥8 (95% CI)	GMT (95% CI)
C	Month 1[(1)]	673	100% (99.5; 100)	13110 (11939; 14395)	224	100% (98.4; 100)	8222 (6808; 9930)
	Year 3[(2)]	449	91.1% (88.1; 93.6)	371 (309; 446)	150	86.0% (79.4; 91.1)	390 (262; 580)
	Year 5[(2)]	236	88.6% (83.8; 92.3)	249 (194; 318)	85	87.1% (78.0; 93.4)	366 (224; 599)
	Year 10[(3)] (Pre-booster)	162	90.1% (84.5; 94.2)	244 (182; 329)	51	82.4% (69.1; 91.6)	177 (86.1; 365)
	(Post-booster)[(3,4)]	162	100% (97.7; 100)	8698 (7391 10235)	51	100% (93.0; 100)	3879 (2715; 5544)
W-135	Month 1[(1)]	678	99.9% (99.2; 100)	8247 (7639; 8903)	224	100% (98.4; 100)	2633 (2299; 3014)
	Year 3[(2)]	449	82.0% (78.1; 85.4)	338 (268; 426)	150	30.0% (22.8; 38.0)	16.0 (10.9; 23.6)
	Year 5[(2)]	236	86.0% (80.9; 90.2)	437 (324; 588)	86	34.9% (24.9; 45.9)	19.7 (11.8; 32.9)
	Year 10[(3)] (Pre-booster)	162	71.6% (64.0; 78.4)	146 (97.6; 217)	51	43.1% (29.3; 57.8)	16.4 (9.2; 29.4)
	(Post-booster)[(3,4)]	162	100% (97.7; 100)	11243 (9367; 13496)	51	100% (93.0; 100)	3674 (2354; 5734)
Y	Month 1[(1)]	677	100% (99.5; 100)	14087 (13168; 15069)	224	100% (98.4; 100)	5066 (4463; 5751)
	Year 3[(2)]	449	93.1% (90.3; 95.3)	740 (620; 884)	150	58.0% (49.7; 66.0)	69.6 (44.6; 109)
	Year 5[(2)]	236	96.6% (93.4; 98.5)	1000 (824; 1214)	86	66.3% (55.3; 76.1)	125 (71.2; 219)
	Year 10[(3)] (Pre-booster)	162	90.7% (85.2; 94.7)	447 (333; 599)	51	49.0% (34.8; 63.4)	32.9 (17.1; 63.3)
	(Post-booster)[(3,4)]	162	100% (97.7; 100)	7585 (6748; 8525)	51	98.0% (89.6; 100)	3296 (1999; 5434)

The analysis of immunogenicity was conducted on the ATP cohort for each time point.

(1) Study MenACWY-TT-036
(2) Study MenACWY-TT-043
(3) Study MenACWY-TT-101
(4) Blood sampling was performed 1 month after a booster dose at Year 10.

*rSBA analysis performed at GSK laboratories for 1 month post primary vaccination samples and at PHE laboratories in UK for the subsequent sampling time points.

hSBA persistence was evaluated up to 5 years after vaccination in adolescents and adults initially vaccinated in Study MenACWY-TT-052 as shown in Table 14 (see section *Special warnings and precautions for use*).

Table 14: hSBA* titres following a single dose of *Nimenrix*™ in adolescents and adults aged 11-25 years and persistence up to 5 years following vaccination (Studies MenACWY-TT-052/059)

Meningococcal group	Time point	N	≥8 (95% CI)	GMT (95% CI)
A	Month 1[(1)]	356	82.0% (77.6; 85.9)	58.7 (48.6; 70.9)
	Year 1[(2)]	350	29.1% (24.4; 34.2)	5.4 (4.5; 6.4)
	Year 5[(2)]	141	48.9% (40.4; 57.5)	8.9 (6.8; 11.8)
C	Month 1[(1)]	359	96.1% (93.5; 97.9)	532 (424; 668)
	Year 1[(2)]	336	94.9% (92.0; 97.0)	172 (142; 207)
	Year 5[(2)]	140	92.9% (87.3; 96.5)	94.6 (65.9; 136)
W-135	Month 1[(1)]	334	91.0% (87.4; 93.9)	117 (96.8; 141)
	Year 1[(2)]	327	98.5% (96.5; 99.5)	197 (173; 225)
	Year 5[(2)]	138	87.0% (80.2; 92.1)	103 (76.3; 140)
Y	Month 1[(1)]	364	95.1% (92.3; 97.0)	246 (208; 291)
	Year 1[(2)]	356	97.8% (95.6; 99.0)	272 (237; 311)
	Year 5[(2)]	142	94.4% (89.2; 97.5)	225 (174; 290)

The analysis of immunogenicity was conducted on the ATP cohort for persistence adapted for each time point.

(1) Study MenACWY-TT-052

(2) Study MenACWY-TT-059

*hSBA analysis performed at GSK laboratories

rSBA titres were determined over a period of 10 years in subjects initially vaccinated with one dose of ***Nimenrix*™** or ACWY-PS at 11 to 55 years of age in Study MenACWY-TT-015. Persistence of rSBA titres was evaluated in two extension studies: MenACWY-TT-020 (up to 5 years) and MenACWY-TT-099 (up to 10 years). Study MenACWY-TT-099 also evaluated the response to a single booster dose of ***Nimenrix*™** administered 10 years following the initial vaccination with ***Nimenrix*™** or ACWY-PS. Results are shown in Table 15.

Table 15: rSBA* titres following a single dose of *Nimenrix*™ (or ACWY-PS) in adolescents and adults aged 11-55 years, persistence up to 10 years, and post-booster administered 10 years following initial vaccination (Studies MenACWY-TT-015/020/099)

Meningo-coccal group	Time point	*Nimenrix*™			ACWY-PS vaccine		
		N	≥8 (95% CI)	GMT (95% CI)	N	≥8 (95% CI)	GMT (95% CI)
A	Month 1[(1)]	323	100% (98.9; 100)	4945 (4452, 5493)	112	100% (96.8, 100)	2190 (1858, 2582)
	Year 4[(2)]	43	95.3% (84.2; 99.4)	365 (226; 590)	17	76.5% (50.1; 93.2)	104 (31.0; 351)
	Year 5[(2)]	51	84.3% (71.4; 93.0)	190 (108; 335)	19	57.9% (33.5; 79.7)	37.0 (12.6; 109)
	Year 10[(3)] (Pre-booster)	155	78.1% (70.7; 84.3)	154 (108; 219)	52	71.2% (56.9; 82.9)	75.1 (41.4; 136)
	(Post-booster)[(3,4)]	155	100% (97.6; 100)	4060 (3384; 4870)	52	100% (93.2; 100)	3585 (2751; 4672)
C	Month 1[(1)]	341	99.7% (98.4; 100)	10074 (8700, 11665)	114	100% (96.8; 100)	6546 (5048; 8488)
	Year 4[(2)]	43	76.7% (61.4; 88.2)	126 (61.6; 258)	17	41.2% (18.4; 67.1)	16.7 (5.7; 48.7)
	Year 5[(2)]	51	72.5% (58.3; 84.1)	78.5 (41.8; 147)	18	38.9% (17.3; 64.3)	17.3 (6.0; 49.7)
	Year 10[(3)] (Pre-booster)	154	90.9% (85.2; 94.9)	193 (141; 264)	52	88.5% (76.6; 95.6)	212 (110; 412)

Table 15: rSBA* titres following a single dose of *Nimenrix*™ (or ACWY-PS) in adolescents and adults aged 11-55 years, persistence up to 10 years, and post-booster administered 10 years following initial vaccination (Studies MenACWY-TT-015/020/099)

Meningo-coccal group	Time point	*Nimenrix*™			ACWY-PS vaccine		
		N	≥8 (95% CI)	GMT (95% CI)	N	≥8 (95% CI)	GMT (95% CI)
	(Post-booster)[3,4]	155	100% (97.6; 100)	13824 (10840; 17629)	52	98.1% (89.7; 100)	3444 (1999; 5936)
W-135	Month 1[1]	340	99.7% (98.4; 100)	8577 (7615; 9660)	114	100% (96.8; 100)	2970 (2439; 3615)
	Year 4[2]	43	90.7% (77.9; 97.4)	240 (128; 450)	17	17.6% (3.8; 43.4)	8.3 (3.6; 19.5)
	Year 5[2]	51	86.3% (73.7; 94.3)	282 (146; 543)	19	31.6% (12.6; 56.6)	15.4 (5.7; 41.9)
	Year 10[3] (Pre-booster)	154	71.4% (63.6; 78.4)	166 (107; 258)	52	21.2% (11.1; 34.7)	10.9 (6.1; 19.3)
	(Post-booster)[3,4]	155	100% (97.6; 100)	23431 (17351; 31641)	52	98.1% (89.7; 100)	5793 (3586; 9357)
Y	Month 1[1]	340	100% (98.9; 100)	10315 (9317; 11420)	114	100% (96.8; 100)	4574 (3864; 5414)
	Year 4[2]	43	86.0% (72.1; 94.7)	443 (230; 853)	17	47.1% (23.0; 72.2)	30.7 (9.0; 105)
	Year 5[2]	51	92.2% (81.1; 97.8)	770 (439; 1351)	19	63.2% (38.4; 83.7)	74.1 (21.9; 250)
	Year 10[3] (Pre-booster)	154	86.4% (79.9; 91.4)	364 (255; 519)	52	61.5% (47.0; 74.7)	56.0 (28.8; 109)
	(Post-booster)[3,4]	155	100% (97.6; 100)	8958 (7602; 10558)	52	100% (93.2; 100)	5138 (3528; 7482)

The analysis of immunogenicity was conducted on the ATP cohorts for 1 month and 5 years post vaccination and the booster ATP cohort.

(1) Study MenACWY-TT-015
(2) Study MenACWY-TT-020
(3) Study MenACWY-TT-099
(4) Blood sampling was performed 1 month after a booster dose at Year 10.

*rSBA analysis performed at GSK laboratories for 1 month post primary vaccination samples and at PHE laboratories in UK for the subsequent sampling time points.

In a separate study (MenACWY-TT-085), a single dose of ***Nimenrix*™** was administered to 194 Lebanese adults aged 56 years and older (including 133 aged 56-65 years and 61 aged >65 years). The percentage of subjects with rSBA titres (measured at GSK's laboratories) ≥128 before vaccination ranged from 45% (group C) to 62% (group Y). Overall, at 1 month post-vaccination the percentage of vaccines with rSBA titres ≥128 ranged from 93% (group C) to 97% (group Y). In the subgroup aged >65 years the percentage of vaccines with rSBA titres ≥128 at 1 month post-vaccination ranged from 90% (group A) to 97% (group Y).

Booster response for subjects previously vaccinated with a conjugate meningococcal vaccine against *Neisseria meningitidis*

***Nimenrix*™** booster vaccination in subjects previously primed with a monovalent (MenC-CRM) or a quadrivalent conjugate meningococcal vaccine (MenACWY-TT) was studied in subjects from 12 months of age onwards who received a booster vaccination. Robust anamnestic responses to the antigen(s) in the priming vaccine were observed (see Tables 6, 7, 11, 13, and 15).

Response to ***Nimenrix™*** in subjects previously vaccinated with a plain polysaccharide meningococcal vaccine against *Neisseria meningitidis*

In Study MenACWY-TT-021 conducted in subjects aged 4.5-34 years, the immunogenicity of ***Nimenrix™*** administered between 30 and 42 months after vaccination with the ACWY-PS vaccine was compared to the immunogenicity of ***Nimenrix™*** administered to age-matched subjects who had not been vaccinated with any meningococcal vaccine in the preceding 10 years. An immune response (rSBA titre ≥8) was observed against all four meningococcal groups in all subjects regardless of the meningococcal vaccine history. The rSBA GMTs were significantly lower in the subjects who had received a dose of ACWY-PS vaccine 30-42 months prior to ***Nimenrix™*** however 100% of subjects achieved rSBA titres ≥8 for all four meningococcal groups (A, C, W-135, Y) (see section *Special warnings and precautions for use*).

Children (2-17 years) with anatomical or functional asplenia

Study MenACWY-TT-084 compared immune responses to two doses of ***Nimenrix™*** given 2 months apart between 43 subjects aged 2-17 years with anatomic or functional asplenia subjects and 43 age-matched subjects with normal splenic function. One month after the first vaccine dose and 1 month after the second dose similar percentages of subjects in the two groups had rSBA titres ≥8 and ≥128 and hSBA titres ≥4 and ≥8.

Impact of a single dose of ***Nimenrix™***

In 2018, the Netherlands added ***Nimenrix™*** to the national immunisation programme as a single dose for toddlers at 14 months of age to replace the meningococcal C conjugate vaccine. A catch-up campaign with a single dose of ***Nimenrix™*** for adolescents 14-18 years of age also initiated in 2018, and it became routine in 2020 leading to a toddler and adolescent national immunisation programme. Within two years, the incidence of meningococcal disease caused by groups C, W, and Y was significantly reduced by 100% (95% CI: 14, 100) in individuals 14-18 years of age, 85% (95% CI: 32, 97) in all vaccine eligible ages (direct effect), and 50% (95% CI: 28, 65) in non-vaccine eligible ages (indirect effect). The impact of ***Nimenrix™*** was primarily driven by a reduction in group W disease.

Preclinical safety data

Non-clinical data reveal no special hazard for humans based on local tolerance, acute toxicity, repeated dose toxicity, developmental/reproductive toxicity and fertility studies.

PHARMACEUTICAL PARTICULARS

Incompatibilities

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.

Shelf Life

The expiry date is indicated on the label and packaging.

Special precautions for storage

Store in a refrigerator (2°C – 8°C).
The solvent may also be stored at ambient temperature (30°C). Solvent must be cooled between +2°C and +8°C before reconstitution.
Do not freeze.
Protect from light.

According to WHO recommendations, once the vaccine has been reconstituted, it should be maintained between +2°C to +8°C and protected from the sunlight; the vial must be discarded at the end of each immunisation session or after 8 hours from reconstitution, whichever comes first.

Nature and contents of container

Powder in a vial containing 1 dose (type I glass) with a stopper (butyl rubber) and 0.5 ml of solvent for 1 dose in a vial (type I glass) with a stopper (butyl rubber).
Pack size of 50.

Special precautions for disposal and other handling

***Nimenrix*™** must be reconstituted by adding the entire contents of the vial of solvent to the vial containing the powder.

1. Withdraw the entire contents of the solvent vial and add the solvent to the powder vial.
2. The mixture should be well shaken until the powder is completely dissolved in the solvent.

The reconstituted vaccine is a clear colourless solution.
The reconstituted vaccine should be inspected visually for any foreign particulate matter and/or variation of physical aspect prior to administration. In the event of either being observed, discard the vaccine.

A new needle should be used to administer the vaccine.

Any unused product or waste material should be disposed of in accordance with local requirements.

Vaccine Vial Monitor (see VVM pictogram at the end of the leaflet)

The Vaccine Vial Monitor (VVM) is part of the cap used for all ***Nimenrix*™** batches supplied by Pfizer Limited. The colour dot that appears on the cap of the vial is a VVM. This is a time-temperature sensitive dot that provides an indication of the cumulative heat to which the vial has been exposed. It warns the end user when exposure to heat is likely to have degraded the vaccine beyond an acceptable level.

The interpretation of the VVM is simple. Focus on the central square. Its colour will change progressively. As long as the colour of this square is lighter than the colour of the ring, then the vaccine can be used. As soon as the colour of the central square is the same colour as the ring or of a darker colour than the ring, then the vial should be discarded.

It is absolutely critical to ensure that the storage conditions specified above (in particular the cold chain) are complied with. Pfizer Limited will assume no liability in the event ***Nimenrix*™** has not been stored in compliance with the storage instructions. Furthermore Pfizer Limited assumes no responsibility in case a VVM is defective for any reason.



WHO Product Information Version number: WHO Product Information 01/Date: [MM/YYYY]
Manufacturer: Pfizer Europe MA EEIG Boulevard de la Plaine 17 1050 Bruxelles Belgium